Accuracy of high-risk HPV DNA PCR, p16
HPV DNA PCR
HPV mRNA
HPV-AHEAD
Oropharyngeal carcinoma
p16(INK4a) IHC
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
06 Aug 2022
06 Aug 2022
Historique:
received:
22
10
2021
accepted:
08
07
2022
entrez:
6
8
2022
pubmed:
7
8
2022
medline:
10
8
2022
Statut:
epublish
Résumé
The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. The accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16 Ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. Single hrHPV DNA PCR and p16
Sections du résumé
BACKGROUND
BACKGROUND
The incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC.
METHODS
METHODS
The accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16
RESULTS
RESULTS
Ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67.
CONCLUSIONS
CONCLUSIONS
Single hrHPV DNA PCR and p16
Identifiants
pubmed: 35933382
doi: 10.1186/s12879-022-07654-2
pii: 10.1186/s12879-022-07654-2
pmc: PMC9357318
doi:
Substances chimiques
Cyclin-Dependent Kinase Inhibitor p16
0
DNA, Viral
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
676Subventions
Organisme : European Commission
ID : FP7-HEALTH-2011-282562
Organisme : Horizon 2020 Framework Programme for Research and Innovation of the European Commission
ID : 847845
Organisme : the Belgian Foundation Against Cancer
ID : IHUVACC
Investigateurs
Christine Carreira
(C)
Sandrine McKay-Chopin
(S)
Rudrapatna S Jayshree
(RS)
Kortikere S Sabitha
(KS)
Ashok M Shenoy
(AM)
Alfredo Zito
(A)
Fausto Chiesa
(F)
Marta Tagliabue
(M)
Mohssen Ansarin
(M)
Subha Sankaran
(S)
Christel Herold-Mende
(C)
Gerhard Dyckhoff
(G)
George Mosialos
(G)
Heiner Boeing
(H)
Xavier Castellsagué
(X)
Silvia de Sanjosé
(S)
Marisa Mena
(M)
Francesc Xavier Bosch
(FX)
Laia Alemany
(L)
Pulikottil Okkuru Esmy
(PO)
Manavalan Vijayakumar
(M)
Aruna S Chiwate
(AS)
Ranjit V Thorat
(RV)
Girish G Hublikar
(GG)
Shashikant S Lakshetti
(SS)
Bhagwan M Nene
(BM)
Amal Ch Kataki
(AC)
Ashok Kumar Das
(AK)
Kunnambath Ramadas
(K)
Thara Somanathan
(T)
Informations de copyright
© 2022. The Author(s).
Références
Int J Cancer. 2007 Oct 15;121(8):1813-20
pubmed: 17546592
Eur J Clin Chem Clin Biochem. 1993 Aug;31(8):531-5
pubmed: 8218586
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
Int J Cancer. 2010 Apr 15;126(8):1882-1894
pubmed: 19795456
Br J Cancer. 2020 Sep;123(7):1114-1122
pubmed: 32624580
Head Neck Oncol. 2010 Jun 29;2:15
pubmed: 20587061
Am J Pathol. 2003 Mar;162(3):747-53
pubmed: 12598309
Int J Cancer. 2015 Jun 15;136(12):2741-51
pubmed: 24740700
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
PLoS One. 2015 Apr 20;10(4):e0124460
pubmed: 25893988
Clin Cancer Res. 2002 May;8(5):1203-9
pubmed: 12006539
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Eur J Cancer. 2014 Oct;50(15):2636-48
pubmed: 25091798
Eur J Cancer. 2013 Nov;49(16):3450-61
pubmed: 23886586
Lancet. 2019 Jan 5;393(10166):5-7
pubmed: 30449624
Oral Oncol. 2012 Dec;48(12):1191-201
pubmed: 22841677
Int J Cancer. 2012 Nov 1;131(9):1969-82
pubmed: 22623137
J Clin Microbiol. 2010 Jan;48(1):143-9
pubmed: 19864475
Int J Cancer. 2015 Apr 1;136(7):1589-99
pubmed: 25104331
Int J Cancer. 2014 May 15;134(10):2366-72
pubmed: 24249631
Int J Cancer. 2001 Apr 15;92(2):276-84
pubmed: 11291057
PLoS One. 2017 Oct 16;12(10):e0184520
pubmed: 29036167
Clin Cancer Res. 2009 Mar 1;15(5):1779-86
pubmed: 19223504
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Br J Cancer. 2013 Jul 9;109(1):172-83
pubmed: 23778529
Int J Cancer. 2007 Dec 1;121(11):2465-72
pubmed: 17680565
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
J Natl Cancer Inst. 2013 Apr 17;105(8):536-45
pubmed: 23503618
Cancer Res. 2012 Oct 1;72(19):4993-5003
pubmed: 22991302
Ann Oncol. 2018 May 1;29(5):1089-1090
pubmed: 29788169
Int J Cancer. 2016 Jul 1;139(1):9-11
pubmed: 26999772
Cancers (Basel). 2020 Nov 29;12(12):
pubmed: 33260360
Mod Pathol. 2013 Feb;26(2):223-31
pubmed: 22996374
Cancer Epidemiol. 2021 Jun;72:101925
pubmed: 33839457
Int J Cancer. 2017 Jul 1;141(1):143-151
pubmed: 28369859
Int J Cancer. 2017 Mar 1;140(5):1186-1198
pubmed: 27859245
Int J Cancer. 2013 Jan 1;132(1):63-71
pubmed: 22514107
J Clin Microbiol. 2006 Jun;44(6):2025-31
pubmed: 16757593
Am J Surg Pathol. 2012 Jul;36(7):945-54
pubmed: 22743284
Lancet Glob Health. 2020 Feb;8(2):e180-e190
pubmed: 31862245
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Sci Rep. 2017 Dec 1;7(1):16715
pubmed: 29196639
J Clin Oncol. 2013 Dec 20;31(36):4550-9
pubmed: 24248688
Int J Cancer. 2014 Feb 1;134(3):497-507
pubmed: 23568556
Cancers (Basel). 2016 Mar 29;8(4):
pubmed: 27043631
J Clin Oncol. 2009 Dec 20;27(36):6213-21
pubmed: 19884544
Cancer Cytopathol. 2012 Oct 25;120(5):294-307
pubmed: 22700382
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2130-5
pubmed: 21245294
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690